Monday, September 14, 2015
Certara, a global biosimulation technology-enabled drug development company, and Paidion Research, a Durham, N.C.-based pediatric CRO, have partnered to promote more efficient and reliable drug development for pediatric patients. The partnership harnesses Certara’s biosimulation (modeling and simulation) and regulatory writing capabilities with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.
With shrinking R&D pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable life cycle management (LCM) strategies in order to maximize revenues and the lifespan of their portfolios, according to business intelligence provider GBI Research.
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has announced a research collaboration with the Japan Pharmaceutical Manufacturers Association (JPMA), a nonprofit organization dedicated to developing innovative pharmaceuticals to improve the health and welfare of people worldwide.
San Francisco-based goBalto, a provider of cloud-based clinical study startup solutions, has announced a two-year partnership with the Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites. goBalto will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.
Icon, a global CRO, is working with IBM to help reduce the time and costs of drug development, while also offering patients enhanced quality-of-care by connecting them to relevant clinical trials. Icon will tap Watson’s cognitive computing power to help automate the cumbersome process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.
Last of three parts